Novartis Flu Vaccine Nightmare Ends; Worries Over Pharmacovigilance Overreaction Remain
This article was originally published in The Pink Sheet Daily
Executive Summary
As Italy, France, Switzerland and Austria lift bans on two Novartis flu vaccines, Germany’s more sober approach to specific batch suspensions proves more palatable for manufacturers.
You may also be interested in...
Fluad Adjuvant Could Come Under Fire At Advisory Committee
CSL’s (formerly Novartis’) flu vaccine was shown to be non-inferior, but not superior, on immunogenicity endpoints compared to an unadjuvanted vaccine in individuals ages 65 years and older.
Germany’s Vaccine Industry In Danger Of Disappearing, Says GSK
GSK believes detrimental government policies such as reference pricing and tendering in the vaccines sector are threatening this part of the pharmaceutical industry, and patient health.
Novartis Flu Vaccine Problems Highlight Lack Of European Co-ordination
Quality issues that have seen two Novartis influenza vaccines suspended in a number of European countries have highlighted the shortfalls of a co-ordinated European approach to such problems.